Bayer has initiated phase III studies of its investigational macrocyclic gadolinium-based contrast agent (GBCA) gadoquatrane.
Bayer's clinical development program is called QUANTI and includes two phase III studies in adults and one pediatric study investigating gadoquatrane for use in MRI across all body regions and across ages from birth to adulthood, the company said.
All trials are investigating gadoquatrane at a dose of 0.04 mmol Gd/kg body weight. The aim of the trials is to demonstrate the lowest gadolinium dose for an MRI contrast agent, Bayer said.
